FDA on another PDC FDA issues alert about clinical trials results for Pepaxto
FDA issues alert about clinical trials results for Pepaxto
Recall melphalan flufenamid another PDC was approved not long ago? They seems to have mortality related issues with their trial, the drug was approved based on accelerated approval designation and still is prescribed to late stage myeloma patients despite the issues. Point is for late stage cancers the agency seems to have lowered the bar as for safety as long as there is some elements of efficacy as these patients have no other options.